Search

Joseph S Adorante

from Irvine, CA
Age ~80
Get Report
Also known as:
Joe S Adorante, Dornate A Joseph
Phone and address:
4652 Sierra Tree Ln, Irvine, CA 92612
(949) 262-0481
Related to:
Mia R Adorante, 34Susan Adorante, 71
Connected to:
Renee P Adorian, 59Alan B Adorjan, 39Almos T Adorjan, 67Erika Adorjan, 88Frank V Adorn, 91Lourdes Adorna, 60Barbara L Adornato, 91Amy C Adornetto, 50Anthony L Adornetto, 58Lisa J Adornetto, 66

Joseph Adorante Phones & Addresses

  • 4652 Sierra Tree Ln, Irvine, CA 92612 (949) 262-0481 (949) 302-1973
  • 5146 Thorn Tree Ln, Irvine, CA 92612
  • Berkeley, CA
  • Newport Beach, CA
  • Santa Ana, CA
  • Orange, CA
  • 4652 Sierra Tree Ln, Irvine, CA 92612

Work

Position: Graphic design intern

Education

Degree: Graduate or professional degree

Resumes

Resumes

Joseph Adorante Photo 1

Graphic Design Intern

View page
Work:

Graphic Design Intern

Publications

Us Patents

Methods And Compositions For Drug Delivery

View page
US Patent:
6350780, Feb 26, 2002
Filed:
Apr 5, 1999
Appl. No.:
09/286147
Inventors:
Michael E. Garst - Newport Beach CA
Joseph S. Adorante - Irvine CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K 31235
US Classification:
514532, 514912
Abstract:
Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having calcium chelating activity. Examples of calcium chelating agents utilized in the pharmaceutical composition and method of treatment are: and lower alkyl and alkoxyalkyl esters thereof. Also disclosed are methods and compositions for delivering a drug within the cytoplasm of a cell having cell surface acetylcholinesterase or acetylcholinesterase receptors, wherein the compositions comprise an apolar prodrug joined to an acetylcholine ester or psuedoacetylcholine group.

Inhibition Of Noninactivating Na Channels Of Mammalian Optic Nerve As A Means Of Preventing Optic Nerve Degeneration Associated With Glaucoma

View page
US Patent:
6420402, Jul 16, 2002
Filed:
Aug 21, 2001
Appl. No.:
09/935554
Inventors:
Joseph S. Adorante - Irvine CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K 31425
US Classification:
514373, 514912
Abstract:
A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na via non-inactivating Na channels, and the lethal elevation of cell Ca due to reversal of the Na /Ca exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na channels in retinal ganglion cells in order to limit Na /Ca exchange in the retinal ganglion cells and prevent buildup of the Ca level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve. Alternately, said invention relates to a method of preventing optic retinal ganglion cell death in a human by administering to the retinal ganglion cells of said human a compound which blocks the non-inactivating sodium ion channel of the retinal ganglion cells.

Inhibition Of Noninactivating Na Channels Of Mammalian Optic Nerve As A Means Of Preventing Optic Nerve Degeneration Associated With Glaucoma

View page
US Patent:
6426358, Jul 30, 2002
Filed:
Sep 14, 2001
Appl. No.:
09/952733
Inventors:
Joseph S. Adorante - Irvine CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K 31425
US Classification:
514373, 514912, 514913
Abstract:
A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na via non-inactivating Na chanels, and the lethal elevation of cell Ca due to reversal of the Na /Ca exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na channels in retinal ganglion cells in order to limit Na /Ca exchange in the retinal ganglion cells and prevent buildup of the Ca level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve. Alternately, said invention relates to a method of preventing optic retinal ganglion cell death in a human by administering to the retinal ganglion cells of said human a compound which blocks the non-inactivating sodium ion channel of the retinal ganglion cells.

Targeting The Reverse Mode Of The Na+/Ca2+ Exchanger For The Treatment Of Optic Neuropathy Associated With Glaucoma And Ischemic Optic Neuropathy

View page
US Patent:
6479458, Nov 12, 2002
Filed:
Nov 8, 2001
Appl. No.:
10/005829
Inventors:
Joseph S. Adorante - Irvine CA
George R. Ehring - Huntington Beach CA
Kara L. Kopper - Rancho Santa Margarita CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 3800
US Classification:
514 11, 514580, 514585, 514912
Abstract:
A method for preventing retinal ganglion cell depth, associated with glaucoma, in an animal of the mammalian species, including humans, comprising the step of administering to ganglion cells and their axons (optic nerve) of said mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having activity for blocking a reverse mode of the sodium/calcium exchanger.

High-Throughput Screen For Identifying Channel Blockers That Selectively Distinguish Transient From Persistent Sodium Channels

View page
US Patent:
6991910, Jan 31, 2006
Filed:
Nov 20, 2001
Appl. No.:
09/989797
Inventors:
Joseph S. Adorante - Irvine CA, US
George R. Ehring - Huntington Beach CA, US
John Donello - Dana Point CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
G01N 33/566
G01N 27/04
C12N 13/00
G01R 27/08
C12M 1/34
US Classification:
435 72, 4351731, 4351734, 4352887, 324447, 324692
Abstract:
A method for identifying a Na channel blocker, including providing a cell containing a Na channel, demonstrating both a transient and a persistent current. The cell includes a potassium (K) channel and a Na/K ATPase (Na pump). A fluorescent dye is disposed into the well. The fluorescent dye is sensitive to change in cell membrane potential in order to enable optical measurement of cell membrane potential. A Na channel blocker, to be identified, is added to the well and a stimulating current is passed through the cell in an amount sufficient to generate an action potential before and after the addition of the Na channel blocker. Thereafter, a change in cell membrane potential is optically measured.

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7060723, Jun 13, 2006
Filed:
Aug 27, 2004
Appl. No.:
10/928949
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 43/06
A61K 31/38
US Classification:
514438, 514443, 514448
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Treating Pain Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7125908, Oct 24, 2006
Filed:
Aug 27, 2004
Appl. No.:
10/928964
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
John E. Donello - Dana Point CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 43/06
A61K 31/38
US Classification:
514438, 514443, 514448
Abstract:
The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7705055, Apr 27, 2010
Filed:
Jan 5, 2006
Appl. No.:
11/326036
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/12
A01N 35/00
A01N 33/18
A01N 33/24
US Classification:
514678, 514679, 514675, 514676
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
Control profile
Joseph S Adorante from Irvine, CA, age ~80 Get Report